Equillium, a Phase 1 biotech developing monoclonal antibody therapies for acute and chronic graft-versus-host disease and asthma, filed on Monday with the SEC to raise up to $86 million in an initial public offering.
The La Jolla, CA-based company was founded in 2017 and plans to list on the Nasdaq under the symbol EQ. Equillium filed confidentially on August 3, 2018. Jefferies, Leerink Partners and Stifel are the joint bookrunners on the deal. No pricing terms were disclosed.
